We reported recently that cobalt chloride-simulated hypoxia and mild hypoxia modified the differentiation of human acute myeloid leukemic (AML) cells, probably acting via a hypoxiainducible factor-1 alpha (HIF-1a)-dependent mechanism. In this study, we investigated the effect of desferrioxamine (DFO), an iron chelator with 'hypoxia-mimetic' activity, on the differentiation of AML cells. The results showed that DFO at nontoxic concentrations induced the differentiation of AML cell lines NB4 and U937, as assessed by morphological criteria and differentiation-associated antigens. DFO-induced differentiation parallel to the rapid accumulation of HIF-1a protein in these two cell lines. Of importance, the transient transfection of HIF-1a cDNA induced U937 cells to develop the differentiationrelated alterations such as growth arrest and increased CD11b expression. Furthermore, the inducible expression of chromosome translocation t(8;21)-generated leukemogenic AML1-ETO fusion gene attenuated DFO-induced differentiation of U937 cells with the decrease of CCAAT/enhancer-binding protein alpha (C/EBPa), a critical factor for granulocytic differentiation. Using immunoprecipitation and luciferase reporter assay, HIF1a was also shown to interact physically with and to increase the transcriptional activity of C/EBPa. Taken together, these results provided novel evidence for a role of HIF-1a in AML cell differentiation, and suggested that C/EBPa might be a downstream effector for HIF-1a-mediated differentiation.
Introduction
Hypoxia-inducible factor-1 (HIF-1) is a critical transcription factor in the mammalian oxygen-sensing pathway. 1 It consists of two basic helix-loop-helix-PAS domain-containing subunits, HIF-1a and HIF-1b/aryl hydrocarbon receptor nuclear translocator. HIF-1b is constitutively expressed. The synthesis of HIF-1a protein is highly regulated by oxygen-independent mechanisms such as mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways, 2 while its degradation is oxygen related. Under normal oxygen tension, the conserved proline residues (mainly proline 564) of HIF-1a protein are hydroxylated by oxygen-and iron-dependent HIF-1a-specific prolyl hydroxylase. 3 The von Hippel-Lindau (VHL) tumor suppressor protein, an E3 ubiquitin-protein ligase, targets the hydroxylated HIF-1a for ubiquitylation and rapid degradation by the proteasome. The degradation of HIF-1a protein is blocked under hypoxia or by the treatment of hypoxia-mimetic agents such as cobalt chloride (CoCl 2 ) and iron chelator desferrioxamine (DFO). 4 In these circumstances, HIF-1a protein enters into the nucleus and heterodimerizes with HIF-1b subunit. 5, 6 Thus, HIF-1 heterodimer contributes to the regulation of angiogenesis, glucose metabolism, cell proliferation/survival and invasion/ metastasis of cancer cells by binding to the hypoxia-responsive element (HRE) in the cis-acting sequences of target genes and activating their transcription. 1, 6 Although the role of HIF-1a in the pathogenesis of solid tumors has been documented, 1 the potential effects of hypoxia and HIF-1 on leukemic cells have only rarely been investigated. Ivanovic et al 7 reported that severe hypoxia (1% O 2 ) favored the self-renewal of hematopoietic stem cells. Hypoxia was also reported to modify proliferation and differentiation of CD34-positive chronic myeloid leukemic cells. 8 Recently, we showed that CoCl 2 -simulated hypoxia and mild hypoxia (2-3% O 2 ) triggered the differentiation of human acute myeloid leukemic (AML) cells with increased HIF-1a protein, which was inhibited by 3-morpholinosydnonimine. 9 Based on these data, we proposed that HIF-1 plays an active role in the differentiation of AML cells. In the present study, we provide novel evidence for the role of HIF-1a in AML cell differentiation by investigating the effect of DFO and the transient ectopic expression of HIF-1a on AML cells. The mechanism of HIF-1a-mediated differentiation was also investigated.
Materials and methods

Cell lines and treatment
Acute promyelocytic leukemic cell line NB4 (kindly provided by Dr Lanotte M in Saint-Louis Hospital, Paris, France), 10 acute monocytic leukemic cell line U937 (from Cell Bank of Shanghai Institutes for Biological Sciences, Shanghai, China) and M2b-type AML cell line Kasumi-1 (from Dr Qi JY in Saint-Louis Hospital, Paris, France), as well as adherent cell lines COS-7 and 293T were used. The U937-A/E 9/14/18 cells with conditional AML-ETO expression was generated by the ecdysone-inducible system from parental U937 cells as described previously. 11 For the induction of AML1-ETO expression in U937-A/E 9/14/18 cells, ponasterone A (Invitrogen, Groningen, the Netherlands) was added to the medium and Western blots were performed to confirm AML1-ETO expression. All leukemic cells were cultured in RPMI-1640 medium (Sigma, St Louis, MI, USA) and adherent cells in DMEM medium (Sigma, St Louis, MI, USA) supplemented with 10% heat-inactivated fetal calf serum (Gibco BRL, Gaithersburg, MD, USA) in 5% CO 2 /95% air humidified atmosphere at 371C. For experiments, cells were seeded at 2-5 Â 10 5 cells/ml and incubated with the indicated concentrations of DFO (Sigma, St Louis, MI, USA) that was dissolved in ultrapure water as a 20 mM stock solution. Owing to the short half-life time of DFO, 12 one-half of the medium was daily replaced with fresh medium plus corresponding concentrations of compounds. Cell viability was determined by the trypan-blue exclusion assay. Growth inhibition rate was calculated by viable cell numbers in treated cells against untreated cells.
Cell differentiation and cell death assays
Cell differentiation was evaluated by morphology with Wright's staining and differentiation antigens (CD11c, CD11b and CD14), the latter being measured on flow cytometry (Beckman-Coulter, Miami, Fl, USA) as described previously. 13 Cell death was evaluated by the annexin V/propidium iodide (PI) double staining assay using the ApoAlert Annexin-V kit from Clontech (Palo Alto, CA, USA) following the manufacturer's instructions.
Semiquantitative RT-PCR
Total RNAs were extracted from cells by TRIzol reagent (Gibco BRL, Gaithersburg, MD, USA) and reverse transcription (RT) was performed by TaKaRa RNA PCR kit (Takara, Dalian, China) following the manufacturer's instructions. HIF-1a and b-actin cDNAs were amplified by the primers: GGA TCC TGG GTA GGA GAT GGA GAT GC (forward) and GCA CTC AAT CAA GAA GTT GC (reverse) for HIF-1a, and CAT CCT CAC CCT GAA GTA CCC (forward) and AGC CTG GAT AGC AAC GTA CAT G (reverse) for b-actin cDNA. PCR amplification was performed for 26 cycles with denaturing at 941C for 30 s, annealing at 581C for 45 s and extension at 721C for 60 s using a GeneAmp PCR System 9600 (Perkin-Elmer, Norwalk, CT, USA). The signal intensities of amplified HIF-1a fragments were normalized against b-actin using a densitometer.
Plasmids
The expression plasmids for pCMV-SPORT-C/EBPa (for CCAAT/ enhancer-binding protein alpha) and its empty vector pCMV-SPORT were gifts of Dr AF Gombart (Cedars-Sinai Medical Center, Los Angeles, CA, USA). pEF-BOS-HIF-1a and its empty vector pEF-BOS were generously provided by Sogawa K (Graduate School of Science, Tohoku University, Japan).
14 The reporter construct pTK81G-CSFR (a generous gift of Dr DG Tenen in Harvard Institutes of Medicine, Boston, MA, USA) contains four consensus C/EBPa binding sites from the G-CSF receptor promoter linked in tandem and cloned into pTK81 luciferase. 15 The empty vector pTK81-luc was described before. 16 Plasmids pFLAG -HIF-1a was constructed as follows: full-length HIF-1a cDNA was amplified from plasmid pEF-BOS-HIF-1a by PCR with the forward primer 5 0 -ATT CAC CAT GGA GGG CGC-3 0 and the reverse primer 5 0 -TCA GTT AAC TTG ATC CAA AGC TC-3 0 . The PCR product was cloned into the KpnI and BamHI sites of expression vector pFLAG CMV-4 (Sigma, St Louis, MO, USA), and the complete insert of the pFLAG-HIF-1a vector was sequenced.
Transient transfection and immunofluorescent staining of HIF-1a
Plasmids pFLAG CMV-4 and pFLAG-HIF-1a were transfected into U937 cells by electroporation. Briefly, 4-5 Â 10 6 U937 cells were resuspended in 0.4 ml serum-free RPMI-1640 medium and electroporated in the presence of 20 mg plasmid DNA. Electroporation were performed at 300 V, 960 mF in 4-mm diameter cuvettes with a BioRad Gene pulser (BioRad, Hercules, CA, USA), and the cuvettes were incubated on ice for an additional 10 min. For analysis of HIF-1a protein expression, immunofluorescent localization of HIF-1a protein was performed using anti-HIF-1a antibody as described previously. 9 Luciferase reporter assay for transcriptional activity of C/ EBPa Determination of nontoxic concentrations of DFO on leukemic cells. (a) NB4 and U937 cells were treated with DFO (K 1 mM; ' 5 mM; m10 mM; E 20 mM) for 6 days. The growth inhibition % was assessed against untreated cells. Every symbol represents the mean of triplicate with less than 10% of variance in an independent parallel experiment. (b) U937 cells were treated with DFO at the indicated concentrations for 6 days and cell death was quantified by annexin V/PI assay on flow cytometry. The mean percentage of annexin V þ /PI À and annexin V þ /PI þ cells is shown in the corresponding quadrant. Similar results were also obtained in DFOtreated NB4 cells (data not shown). All experiments were repeated up to three times with similar results.
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Y Jiang et al internal control Renilla luciferase plasmid pRL null and 250 ng of pCMV-SPORT-C/EBPa and/or pEF-BOS-HIF-1a vectors by Polyfect as described by the manufacturer (Qiagen, Hilden, Germany). The same concentrations of the empty vectors were used as controls. Firefly luciferase activities from the pTK81G-CSFR and Renilla luciferase activity from the pRL null were determined 24 h after transfection using the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activities were normalized by the Renilla luciferase values.
Co-immunoprecipitation (co-IP) of C/EBPa and HIF-1a proteins
COS-7 cells and 293T cells were transiently transfected with pCMV-SPORT-C/EBPa (1 mg) and pEF-BOS-HIF-1a (1 mg) expression vectors by Polyfect as described above. After 48 h, wholecell extracts were prepared in 300 ml of lysis buffer (50 mM HEPES, 50 mM NaCl, 0.1% Tween-20, 10% glycerol, 20 mM sodium pyrophosphate, 1 mM dithiothreitol, plus protease inhibitors) and incubated with anti-HIF-1a or anti-C/EBPa antibody and protein A plus-agarose (Santa Cruz, CA, USA) overnight at 41C. Preimmune mouse and rabbit IgG were used as negative controls. After co-IP, the beads were intensively washed and precipitated materials were used for Western blots.
Western blot
Cells were dissolved in lysis buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerin, 200 mM dithiothreitol, plus protease inhibitors) and quantified for proteins by DC protein assay kit II (Bio-Rad, Hercules, CA, USA). Equal amounts of protein extracts were loaded to SDS-PAGE gel and transferred to Immobilon-PVDF membranes (Schleicher&Schuell, Dassel, Germany). The blot was blocked in 5% fat-free milk and then incubated with mouse monoclonal anti-HIF-1a (Becton Dickinson, Palo Alto, CA, USA), mouse monoclonal anti-HIF-1b, rabbit polyclonal anti-C/EBPa, mouse monoclonal anti-b-actin or goat polyclonal anti-ETO antibodies (Santa Cruz, CA, USA) in a 5% fat-free milk solution. The immunocomplexes were visualized by using a chemiluminescent kit (Amersham, Bukinghamshire, UK).
Statistical analysis
The Student's t-test was used to compare the difference between two different groups. Po0.01 was considered to be statistically significant.
Results
DFO triggers morphological and functional differentiation of AML cells
We first evaluated nontoxic concentrations of DFO on NB4 and U937 cells using trypan-blue exclusion assay and annexin V/PI double staining-based flow cytometry analysis. As shown in Figure 1a , the treatment with DFO produced dose-dependent growth inhibition in NB4 and U937 cells. At concentrations of (Figure 1 ). At a low concentration (1 mM), DFO had no effects on either cell growth or cell viability in these two cell lines. Next, we investigated whether DFO at nontoxic concentrations induces leukemic cell differentiation. For these experiments, NB4 and U937 cells were treated with various nontoxic concentrations of DFO for 6 days. As can be seen in Figure 2a , the treatment with DFO at 5-20 mM but not at 1 mM for 6 days induced NB4 and U937 cells to exhibit differentiation-related morphological features such as condensed chromatin, a decrease in nuclei/cytoplasm ratio with indented, distorted and even horseshoe-shaped nuclei. The same concentrations of DFO also induced the time-dependent increase in the expression of CD11b and CD11c but not CD14 (Figure 2b and data not shown) in both NB4 and U937 cells. In total, these experiments indicated that DFO could induce differentiation of leukemic NB4 and U937 cells.
DFO at differentiation-inducing concentrations rapidly increases HIF-1a protein
To examine whether DFO at differentiation-inducing concentrations affects HIF-1a expression, NB4 and U937 cells were treated with DFO at concentrations ranging from 1 to 10 mM. Then, HIF-1a mRNA and protein levels were determined by semiquantitative RT-PCR and Western blot, respectively. The results showed that DFO did not alter the levels of HIF-1a
mRNA at all time points tested in NB4 (Figure 3a ) and U937 cells (Figure 3b ). However, DFO at differentiation-inducing concentrations (5 and 10 mM but not 1 mM) did increase HIF-1a protein but not HIF-1b protein in these two cells (Figure 3 ). Of note, DFO-induced accumulation of HIF-1a protein rapidly reached a peak after treatment with 10 mM of DFO and gradually decreased to a lower level, even though DFO was added every day.
Transient overexpression of HIF-1a induces differentiation of leukemic U937 cells
In order to confirm the role of HIF-1a in leukemic cell differentiation, HIF-1a-expressing vector (pFLAG-HIF-1a) and empty vector (pFLAG CMV-4) were, respectively, transfected into U937 cells. Indirect immunofluorescent analysis with anti-HIF-1a antibody showed that 72 h after transfection, empty vector-transfected cells had only slight background staining, but pFLAG-HIF-1a-transfected cells exhibited strong staining in the cytoplasm and nucleus (Figure 4a ), indicating effective transfection of HIF-1a. Analyses of the proliferative ability and CD11b expression in these cells indicated that cell growth in HIF-1a-transfected cells was decreased by 25-35% without any changes in cell death, compared to empty vector-transfected cells and nontransfected cells. More importantly, some maturating cells could also be seen in HIF-1a-transfected cells under microscope (data not shown). Moreover, CD11b þ cell % was 37.4719.9% in HIF-1a-transfected cells, which was significantly higher than those in empty vector-transfected cells (10.378.35%) and -untransfected cells (14.374.65%; Figure 4b ). It should be pointed out that although greater variations existed, possibly due to different transfection efficien- Effects of transient transfection of HIF-1a on the differentiation of U937 cells. Plasmid pFLAG-CMV4 and pFLAG-HIF1a were transfected into U937 cells, respectively. After 72 h, cells were stained by immunofluorescence for HIF-1a protein (a) and CD11b þ cell % was measured on flow cytometry (b). Po0.01, compared with untransfected cells and pFLAG-CMV4-transfected cells. All experiments were repeated five times with duplicates and the data represent an independent experiment (a) or means7s.d. of all experiments (b).
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Y Jiang et al cies in the five repeats of experiments, all separate experiments with duplicates showed that CD11b þ cell % in HIF-1a-transfected cells was more than two-to four-folds than those in empty vector-transfected and -untransfected cells. Inducible expression of AML1-ETO increases HIF-1a expression in U937 cells. (a) U937-A/E 9/14/18 cell and its parental U937 cell as well as Kasumi-1 cell were treated with or without 5 mM ponasterone A for 48 h. AML1-ETO and C/EBPa proteins were blotted with b-actin as loading control. (b) U937-A/E 9/14/18 (top) and its parental U937 cells (bottom) were treated with 5 mM ponasterone A for the hours as indicated. HIF-1a mRNA was measured by semiquantitative RT-PCR with b-actin as an internal control. The signal intensities of amplified HIF-1a and b-actin were evaluated using a densitometer and ratio of HIF-1a mRNA against b-actin mRNA is indicated. (c) U937-A/E 9/14/18 cells were treated with 10 mM DFO and/or 5 mM ponasterone A for 48 h, and HIF-1a proteins were analyzed by Western blot with b-actin as loading control. Inducible AML1-ETO expression is also shown at the bottom panel.
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Inducible expression of AML1-ETO fusion gene significantly inhibits DFO-induced differentiation
In the next phase of analysis, we extended our study to investigate the possible effect of chromosomal translocation t(8;21)-generated leukemogenic AML1-ETO fusion gene on DFO-induced differentiation, because the fusion gene was shown to exhibit the inhibitory effect on the differentiation of AML cells induced by a wide spectrum of differentiation-inducing agents, as reviewed by Peterson and Zhang. 17 For this purpose, U937-A/E 9/14/18 cells were incubated with 5 mM ponasterone A, which induced AML1-ETO expression in the cells in a time-dependent manner (Figure 5a) . Notably, such an effect could not be seen in U937 and Kasumi-1 cells (Figure 6a) , indicating the specificity of AML1-ETO induction by ponasterone A. As depicted in Figure 5b , DFO at 5 mM and 10 mM induced U937-A/E 9/14/18 cells to differentiate in the absence of ponasterone A, as assessed by CD11b expression (top panels) and mature-related morphologic features (data not shown). More intriguingly, DFO-induced differentiation in the cells was significantly inhibited by the addition of ponasterone A, that is, AML1-ETO expression (bottom panels of Figure 5b ). Of note, ponasterone A did not produce such an effect in parental U937 cells (data not shown). Furthermore, DFO failed to induce the differentiation in Kasumi-1 cells (Figure 5c ), which expressed a high level of endogenous AML1-ETO protein (far right lane of Figures 5a and 6a) . These experiments indicated that AML1-ETO expression blocked DFO-induced cell differentiation. Unexpectedly, the treatment with ponasterone A (5 mM) produced a time-dependent increase of HIF-1a mRNA in U937-A/E 9/14/18 cells but not in its parental U937 cells (Figure 6b) . Furthermore, ponasterone A also elevated DFO-accumulated HIF-1a protein in U937-A/E 9/14/18 cells, although its treatment alone failed to increase HIF-1a protein (Figure 6c ). These results suggested that AML1-ETO increased HIF-1a transcription, but failed to stabilize HIF-1a protein.
HIF-1a interacts with and enhances the transcriptional activity of C/EBPa protein
The contradictory discovery that AML1-ETO expression blocked DFO-induced differentiation but potentiated HIF-1a expression in combination with DFO led us to hypothesize that HIF-1a promotes maturation of U937 cells by regulating other differentiation-related molecules that are inhibited by AML1-ETO fusion protein. It has been widely reported that the AML1-ETO expression resulted in an inhibition of C/EBPa expression, 18, 19 as shown in Figure 6a . To evaluate whether C/EBPa contributes to HIF-1a-mediated differentiation, we decided whether HIF-1a interacts with and affects the transcriptional activity of C/EBPa. Thus, COS-7 cells (right panel of Figure 7a ) and 293T cells (left panel of Figure 7a ) were transfected with HIF-1a and C/EBPaexpressing vectors. At 48 h after transfection, cell extracts were incubated with antibodies against either HIF-1a or C/EBPa, precipitated by protein A-Sepharose, resolved in SDS-PAGE and analyzed by Western blots with anti-HIF-1a (top of Figure 7a ) and anti-C/EBPa antibodies (bottom of Figure 7a ). As shown in Figure 7a , HIF-1a and C/EBPa proteins were detected in the whole-cell extracts, indicating the effective transfection. Anti-HIF-1a or anti-C/EBPa antibody but not preimmune rabbit or mouse serum precipitated the corresponding protein, confirming the specificity and effectiveness of the co-IP assay. Interestingly, anti-C/EBPa antibody was able to precipitate HIF-1a protein, supporting a physical interaction of these two proteins. However, anti-HIF-1a antibody failed to precipitate C/EBPa protein, possibly because an interaction of C/EBPa with HIF-1a covered the epitope of the anti-HIF-1a antibody.
In order to further investigate whether HIF-1a affects the transcriptional activity of C/EBPa, COS-7 cells were cotransfected with HIF-1a and/or C/EBPa-expressing vectors together with a luciferase reporter construct containing four C/EBPa binding sites that has been used for the specific analysis of transcriptional activity of C/EBPa protein. 18 As shown in Figure 7b , transfection of 250 ng C/EBPa but not of 250 ng HIF-1a expression vector significantly increased the luciferase activity of the reporter construct. More importantly, The C/EBPainduced luciferase activity was greatly enhanced by cotransfection with HIF-1a expression vector, suggesting that HIF-1a potentiated the transcriptional activity of C/EBPa. The similar result was also seen in 293T cells (data not shown).
Discussion
We reported previously that CoCl 2 and moderate hypoxia modified leukemic cell differentiation possibly via the mediation of HIF-1a protein. 9 In the present study, we found that another hypoxia-mimetic agent DFO also induced the differentiation in two AML cell lines NB4 and U937 at relatively low concentrations, as demonstrated by morphological criteria and increased granulocytic differentiation-related antigens CD11b and CD11c. At differentiation-inducing concentrations, DFO also induced a rapid but transient accumulation of HIF-1a protein, which was in agreement with previous observations in other cells treated with high concentrations of DFO. 4, 20 Such a transient HIF-1a accumulation was recently proposed to be associated with negative feedback by increased natural antisense HIF-1a in lung epithelial cells. 21 Of great importance, transient overexpression of HIF-1a induced U937 cell differentiation as well as growth arrest. Of note, HIF-1a was also distributed in the cytoplasm besides nuclei, which was possibly due to the speed of synthesis of the protein was larger than that of its degradation that occurred in the cytoplasm. It is worth noting that we failed to create a cell line with stable HIF-1a expression despite several attempts, which might be due to the overexpression of HIF-1a resulting in leukemic cell maturation and preventing cells from continuous growth. In total, these data in combination with our previous discoveries 9 proposed the active role of HIF-1a in leukemic cell differentiation induced at least by hypoxia and hypoxia-mimetic agents.
More interestingly, we showed that DFO failed to induce the differentiation of Kasumi-1 cells that had higher endogenous expression of AML1-ETO gene, which is generated by specific chromosome translocation t(8;21)(q22;q22), which is associated with 12% of de novo AML cases and up to 40% of the M2-type AML of the French-American-British classification. 17 Notably, we previously reported that CoCl 2 at 25 and 50 mM induced the differentiation of Kasumi-1 cells to a degree less than that observed in U937 and NB4 cells as determined by CD11b and CD11c levels. 9 In the current study, however, CoCl 2 at the same concentrations failed to induce Kasumi-1 cell differentiation (data not shown). This discrepancy might be due to the different origins of the Kasmusi-1 cell lines. The Kasumi-1 cells used in this study was from a laboratory in Paris as described in the Materials and methods section, while those used in the previous report were obtained from Dr Kamada in Japan 22 and kept in our laboratory for a long time. It is possible that these cells with different origins had a differential expression of AML1-ETO gene. Although this hypothesis could not be tested due to the lack of previous Kasumi-1 cells, the fact that CoCl 2 induced differentiation of fresh bone marrow cells from two out of four cases of M2-type AML patients containing AML-ETO fusion gene 9 possibly supported that the expression level of AML1-ETO fusion gene interferes with DFO-induced differentiation in M2b-type AML cells. Indeed, inducible AML-ETO expression inhibited DFO-induced cell differentiation in the ecdysoneinducible system from parental U937 cells. These experiments suggested that AML1-ETO could inhibit DFO-induced leukemic cell differentiation. As documented, AML1-ETO expression inhibited leukemic cell differentiation induced by many inducers and the silence of AML1-ETO expression by small interfering RNAs enhanced myeloid differentiation of t(8;21)-positive leukemic cells. 17, [23] [24] [25] [26] [27] To provide some clues for understanding mechanisms of the action of HIF-1a in leukemic cell differentiation, we investigated the effect of leukemogenic AML1-ETO fusion gene on HIF-1a. More surprisingly, we showed that the inducible expression of AML1-ETO increased HIF-1a transcription in U937 cells via an undefined mechanism. The paradox of the upregulation of HIF-1a expression with the inhibition of DFO-induced differentiation by AML1-ETO prompted us to speculate that HIF-1a-mediated differentiation requires the contribution of other differentiation-related factors that are blocked by AML1-ETO. One such factor may be C/ EBPa, a member of the leucine zipper family of transcription Figure 8 A speculative sketch of mechanisms of DFO-induced differentiation of leukemic cells. DFO at differentiation-inducing concentrations induces the accumulation of HIF-1a protein that interacts with C/EBPa protein and enhances the transcription activity of C/EBPa. Finally, C/EBPa mediates leukemic cell differentiation.
AML1-ETO increases HIF-1a mRNA but fails to stabilize HIF-1a protein. Thus, HIF-1a protein is increased in the presence of DFO, which blocks the degradation of HIF-1a protein.
AML1-ETO inhibits C/EBPa expression, and decreased transcriptional function of C/EBPa protein. Therefore, the terminal effect of AML1-ETO is to block DFO-induced differentiation.
factors, which bind DNA as homodimers. As a critical transcription factor for leukemic cell differentiation, 28, 29 expression of C/EBPa in a myeloid cell line and in multipotential avian progenitor cells leads to granulocytic differentiation. 30, 31 The mutations of C/EBPa gene have been identified in many different subtype of AML cells, 18, 32 proposing that C/EBPa plays an important role in the pathogenesis of human AML. As such, the t(8;21)-associated AML1-ETO fusion protein leads to the downregulation of C/EBPa. 18 In addition, AML-1-ETO was also reported to physically interact in vivo with C/EBPa and thus completely inhibit C/EBPa-dependent transcription. 19 In agreement with these reports, U937-A/E 9/14/18 cells and Kasumi-1 cells had undetectable C/EBPa protein in the presence of AML1-ETO expression. Furthermore, we demonstrated a physical interaction between HIF-1a and C/EBPa proteins using co-IP assay. Although such an interaction remains to be further confirmed by other methods, the overexpression of HIF-1a significantly potentiated the transcriptional activity of C/EBPa in cotransfection system. These experiments propose that C/EBPa, a critical factor in leukemic cell differentiation, might play an essential role in HIF-1a-mediated leukemic cell differentiation. It is worthwhile to point out that NB4 cells expressed PML-RARa fusion protein, which is generated by t(15;17), 10 was also reported to inhibit the action of C/EBPa. 33 However, NB4 cells displayed higher sensitivity to DFO-induced differentiation. We speculate that the interaction of HIF-1a and C/EBPa proteins possibly sequester or overcome the effect of PML-RARa on C/ EBPa action, which remains to be addressed.
According to our data, we propose a speculative scheme for mechanisms of DFO-induced differentiation (Figure 8 ). In short, the upregulation of HIF-1a protein by DFO and maybe also by hypoxia and CoCl 2 leads to a potentiation of the action of C/ EBPa protein by their interaction, the latter eventually contributing to differentiation of AML cells. On the contrary, the expression of AML1-ETO results in a suppression of C/EBPa expression and then blocks the DFO-induced cell differentiation, although the fusion gene increases HIF-1a transcription. Taken together, these results provide novel evidence for an active role of HIF-1a protein in AML cell differentiation, and suggest that C/EBPa may be a downstream effector for HIF-1a-mediated differentiation.
